hivrel
diarrhoea
import
caus
morbid
mortal
hiv
infect
cytomegaloviru
wellestablish
caus
diarrhoea
role
enter
virus
less
clear
discuss
clinic
manifest
diseas
mechan
diagnost
techniqu
current
treatment
manag
infect
review
cmv
infect
gi
tract
patient
aid
diminish
greatli
follow
initi
haart
aid
patient
cmv
success
discontinu
anticmv
treatment
without
reactiv
diseas
parallel
reduct
cmv
viraemia
pathogen
role
cmv
infect
well
establish
although
retin
common
manifest
infect
introduct
combin
antiretrovir
therapi
gi
infect
oesophagu
stomach
small
bowel
colon
occur
patient
cours
hiv
infect
incid
cmv
retin
declin
follow
introduct
haart
concomit
increas
surviv
also
presum
true
gi
cmv
although
publish
data
limit
although
cmv
infect
part
gi
tract
common
site
infect
colon
common
manifest
cmv
coliti
chronic
intermitt
diarrhoea
associ
abdomin
pain
diseas
also
associ
mild
sever
rectal
bleed
abdomin
pain
absenc
diarrhoea
addit
fever
common
present
pain
preced
develop
toxic
megacolon
intestin
perfor
rare
clearli
life
threaten
colon
cmv
infect
occur
associ
infect
elsewher
gi
tract
includ
oesophagu
usual
result
dysphagia
odynophagia
pancreaticobiliari
tree
result
aidsrel
cholangiopathi
pancreat
manifest
pain
upper
abdomen
gi
infect
also
herald
cmv
retin
care
retin
assess
therefor
essenti
group
mechan
cmv
induc
gi
diseas
poorli
understood
cmv
infect
mucosa
associ
mark
local
inflammatori
respons
might
role
induc
mucos
ulcer
wilcox
colleagu
found
mrna
level
proinflammatori
cytokin
tumour
necrosi
factor
elev
oesophag
mucosa
patient
cmv
oesophag
return
normal
follow
treatment
cmv
ref
similarli
sharpston
et
al
note
increas
level
faecal
sampl
patient
gi
cmv
ref
enter
ischaemia
result
cmvassoci
vascul
might
conceiv
play
role
gi
cmv
ref
although
hypothesi
remain
unexplor
cmv
enter
similar
mechan
invok
explain
aetiopathogenesi
opportunist
viral
enter
potenti
import
gastrointestin
gi
manifest
hivrel
diseas
howev
except
cytomegaloviru
cmv
human
herp
simplex
viru
hsv
establish
aetiolog
agent
diseas
gi
tract
patient
hiv
role
enter
virus
remain
controversi
hiv
patient
chronic
diarrhoea
pathogen
readili
identifi
use
wellestablish
diagnost
protocol
includ
stool
cultur
microscopi
histolog
examin
biopsi
obtain
endoscopi
upper
lower
gi
tract
exampl
use
protocol
case
persist
diarrhoea
relat
infect
identifi
bacteria
parasit
cmv
cmv
alon
account
case
addit
techniqu
stool
electron
microscopi
specif
immunolog
stain
implic
enter
virus
case
role
virus
socal
pathogenneg
diarrhoea
remain
uncertain
clinic
import
hiv
enteropathi
probabl
limit
sever
virus
includ
astroviru
picobirnaviru
small
round
structur
viru
srsv
rotaviru
implic
hivrel
diarrhoea
addit
adenoviru
associ
persist
diarrhoea
patient
characterist
adenoviru
coliti
evid
patholog
role
virus
discuss
tabl
well
establish
cmv
infect
gi
tract
caus
diarrhoea
method
diagnosi
current
treatment
review
spectrum
diseas
morbid
mortal
among
hiv
patient
alter
dramat
sinc
widespread
introduct
highli
activ
antiretrovir
therapi
haart
opportunist
infect
includ
spectrum
upper
lower
gi
manifest
cmv
infect
describ
definit
diagnosi
cmv
enterocol
requir
intestin
biopsi
prospect
studi
wilcox
colleagu
evalu
patient
hiv
sigmoidoscopi
colonoscopi
chronic
diarrhoea
abdomin
pain
occur
patient
respect
present
lower
gi
bleed
previou
histori
diarrhoea
endoscop
appear
heterogen
three
main
categori
identifi
coliti
associ
ulcer
ulcer
alon
coliti
alon
subepitheli
haemorrhag
common
group
total
patient
underw
complet
endoscopi
caecum
four
diseas
proxim
splenic
flexur
without
distal
involv
therefor
inaccess
flexibl
sigmoidoscopi
contrast
earli
report
suggest
higher
rate
rightsid
coliti
group
assess
vari
endoscop
appear
cmv
infect
oesphagu
multipl
ulcer
locat
middl
lower
oesophagu
identifi
patient
usual
less
cm
diamet
superfici
heterogen
manifest
cmv
diseas
colon
oesophagu
make
biopsi
essenti
accur
diagnosi
histolog
base
diagnosi
cmv
enterocol
depend
larg
identif
characterist
cytomegaloviru
inclus
bodi
sampl
usual
obtain
base
cmv
ulcer
addit
specif
immunoperoxidas
stain
cmv
also
use
identifi
gi
diseas
posit
stain
like
edg
ulcer
author
claim
greater
sensit
compar
convent
histolog
although
unclear
report
rigor
inclus
bodi
exclud
valu
viral
cultur
intestin
biopsi
limit
timeconsum
procedur
furthermor
cmv
viraemia
occur
absenc
mucos
diseas
lead
falseposit
diagnosi
biopsi
contamin
blood
although
use
situ
hybrid
assess
gi
cmv
diseas
sensit
specif
probabl
offer
littl
addit
benefit
convent
histolog
use
pcr
detect
cmv
might
also
sensit
use
standard
histolog
techniqu
howev
evid
suggest
techniqu
lack
specif
normal
gi
biopsi
posit
pcr
furthermor
situ
hybrid
risk
pcr
give
falseposit
result
patient
viraemia
sensit
convent
histolog
viral
cultur
pcr
immunohistochemistri
summar
tabl
ref
cott
colleagu
monitor
cmv
dna
level
treatment
level
broadli
reflect
clinic
respons
newer
techniqu
avail
monitor
natur
histori
progress
cmv
diseas
posthaart
era
salmonceron
colleagu
compar
three
blood
marker
cmv
level
antigenaemia
viral
cultur
plasma
level
cmv
dna
level
late
cmv
mrna
assess
cmvdiseas
progress
patient
haart
multivari
analysi
plasma
cmv
dna
rais
antigenaemia
count
cell
l
identifi
independ
risk
factor
develop
cmv
diseas
other
compar
techniqu
retin
assess
evalu
cmv
retin
digen
hybrid
captur
cmv
dna
system
sensit
retin
assess
similar
cumbersom
antigenaemia
assay
sensit
tabl
glossari
cholangiopathi
patholog
relat
biliari
tree
crohn
diseas
chronic
inflammatori
condit
gastrointestin
tract
caus
remain
unknown
enter
viru
viru
tissu
tropism
intestin
tract
odynophagia
pain
swallow
oesophag
inflamm
oesophagu
pancreat
inflamm
pancrea
retin
inflamm
retina
lead
visual
impair
blind
toxic
megacolon
patholog
dilat
colon
associ
certain
infect
inflammatori
condit
bowel
viraemia
bloodborn
carriag
viru
treatment
cmv
enterocol
requir
parenter
therapi
either
ganciclovir
mg
kg
twice
daili
foscarnet
mg
kg
twice
daili
caus
sever
side
effect
although
agent
improv
endoscop
symptomat
marker
cmv
diseas
surviv
benefit
uncertain
need
reevalu
follow
introduct
haart
ref
ganciclovir
caus
sever
bone
marrow
depress
result
anaemia
neutopaenia
foscarnet
caus
sever
renal
impair
although
concomit
infus
normal
salin
larg
diminish
risk
renal
damag
open
label
random
studi
compar
twoweek
cours
foscarnet
ganciclovir
dose
state
signific
differ
respons
gi
cmv
diseas
two
therapi
approxim
patient
good
clinic
endoscop
respons
disappear
inclus
bodi
determin
histolog
relaps
occur
within
ten
week
least
patient
surviv
without
haart
week
surprisingli
blanshard
colleagu
found
mainten
therapi
increas
time
taken
relaps
gi
diseas
although
number
small
alloc
mainten
therapi
random
use
oral
ganciclovir
mainten
therapi
retin
effect
specif
evalu
gi
diseas
efficaci
treatment
oral
ganciclovir
primari
prophylaxi
cmv
diseas
disput
concern
develop
viral
resist
rais
hope
newer
agent
cidofovir
famiclovir
valganciclovir
formivirsen
role
manag
cmv
diseas
encouragingli
advent
haart
led
mark
reduct
mortal
morbid
hiv
patient
haart
result
remiss
previous
persist
opportunist
infect
includ
cmv
infect
howev
develop
viral
resist
difficulti
complianc
could
lead
breakthrough
hiv
viraemia
reemerg
reacquisit
opportunist
gi
infect
unfortun
combin
antiretrovir
therapi
costli
consequ
unavail
vast
major
hiv
patient
worldwid
patient
haart
stabl
cmv
retin
count
cell
l
abl
success
discontinu
anticmv
mainten
therapi
without
relaps
retin
develop
extraocular
diseas
mean
followup
period
month
importantli
immun
reactiv
retin
occur
patient
start
haart
discontinu
anticmv
treatment
substanti
visual
loss
minor
patient
macdonald
colleagu
report
similar
find
although
followup
period
consider
shorter
comment
immun
reactiv
retin
other
find
haart
caus
signific
progress
declin
cmv
viraemia
absenc
specif
anticmv
treatment
intrigu
specul
possibl
occurr
immun
reactiv
enter
patient
gi
cmv
describ
date
mani
question
remain
host
immun
respons
opportunist
infect
follow
immun
reconstitut
haart
specif
immun
mechan
lead
diseas
resolut
follow
haart
tcell
repertoir
expand
follow
reconstitut
recogn
new
cmv
antigen
secondari
prophylaxi
discontinu
patient
respond
haart
immun
consequ
retrovir
rebound
haart
fail
cmv
indic
monitor
predict
relaps
patient
haart
adenoviru
report
caus
infect
immunosuppress
group
includ
individu
primari
immunodefici
bonemarrowtranspl
patient
hiv
patient
dionisio
colleagu
report
increas
stool
carriag
subgenu
f
type
adenoviru
increas
immunosuppress
janoff
colleagu
first
describ
adenoviru
coliti
electron
microscopi
cultur
colon
biopsi
hiv
patient
investig
diarrhoea
identifi
adenoviru
five
patient
colonoscopi
reveal
mild
inflammatori
chang
two
patient
focal
necrosi
amphophil
nuclear
inclus
within
degener
epitheli
cell
shown
use
light
microscopi
electron
microscopi
reveal
characterist
hexagon
adenoviru
particl
within
inclus
fig
maddox
et
al
confirm
characterist
featur
found
specif
immunostain
adenoviru
sensit
specif
identif
adenoviru
inclus
pathogen
role
adenoviru
remain
unclear
group
patient
frequent
coinfect
known
pathogen
thoma
cowork
report
adenoviru
coliti
significantli
like
associ
chronic
diarrhoea
schmidt
colleagu
abl
detect
adenoviru
aid
patient
sever
immunosuppress
although
sever
immunosuppress
group
adenoviru
detect
frequent
patient
diarrhoea
without
vs
posit
neg
correl
adenoviru
diarrhoea
report
group
tabl
studi
indic
strong
associ
infect
adenoviru
coinfect
pathogen
particular
cmv
difficult
therefor
ascrib
pathogen
role
viru
certainti
infect
enterocyt
hiv
well
document
implic
caus
socal
hiv
enteropathi
morpholog
function
abnorm
gut
describ
absenc
detect
pathogen
clinic
import
hiv
enteropathi
probabl
limit
certainli
pathogenneg
diarrhoea
compar
short
live
associ
good
prognosi
sever
enter
virus
associ
hivrel
diarrhoea
grohman
colleagu
examin
stool
specimen
patient
without
diarrhoea
electron
microscopi
polyacrylamidegel
electrophoresi
enzym
immunoassay
use
examin
sampl
rotaviru
adenoviru
calciviru
picobirnaviru
pair
sera
also
analys
antibodi
norwalk
picobirnaviru
overal
viru
detect
patient
diarrhoea
without
diarrhoea
astroviru
picobirnaviru
calciviru
includ
srsv
adenoviru
identifi
significantli
often
patient
diarrhoea
unfortun
coinfect
known
pathogen
evalu
systemat
inform
regard
rel
distribut
acut
chronic
diarrhoea
provid
schmidt
colleagu
detect
viru
stool
sampl
hivinfect
patient
adenoviru
coronaviru
detect
frequent
patient
diarrhoea
without
vs
vs
respect
associ
sever
immunosuppress
thea
et
al
found
associ
enter
viru
shed
diarrhoea
studi
perform
zair
overal
group
identifi
enter
viru
includ
rotaviru
srsv
coronaviru
adenoviru
sampl
analys
note
trend
toward
increas
shed
greater
immunosuppress
find
common
cunningham
colleagu
associ
rotaviru
prolong
diarrhoea
hiv
patient
detect
enzym
immunoassay
also
report
although
group
support
find
data
select
studi
evalu
enter
viru
carriag
hiv
patient
summar
tabl
summari
data
regard
associ
noncmv
enter
viru
infect
diarrhoea
conflict
best
evid
relat
adenoviru
infect
although
pathogen
role
far
certain
specul
mani
virus
caus
selflimit
acut
diarrhoea
case
adenoviru
act
cofactor
cmv
infect
littl
known
therapeut
option
put
pathogen
although
ribavarin
might
effect
treatment
adenoviru
rcg
pollok
unpublish
impact
haart
noncmv
enter
viru
infect
yet
evalu
warrant
studi
new
develop
diagnosi
treatment
cmv
establish
assay
cmv
dna
cmv
antigen
assay
offer
prospect
cmv
surveil
develop
endorgan
diseas
allow
tailor
introduct
prophylaxi
oral
ganciclovir
valganciclovir
two
greater
bioavail
potenti
use
prophylact
agent
second
gener
cmv
treatment
becom
avail
evalu
larg
transplant
patient
advent
haart
dramat
reduc
occurr
opportunist
infect
includ
cmv
consequ
made
evalu
newer
agent
difficult
patient
hiv
haart
unlik
wide
avail
develop
world
immedi
futur
diarrhoeal
diseas
continu
contribut
death
toll
hiv
patient
countri
role
noncmv
enter
infect
hivrel
diarrhoea
remain
uncertain
unless
research
undertaken
import
virus
hivrel
diarrhoea
unlik
establish
specif
immun
mechan
lead
diseas
resolut
follow
haart
role
noncmv
enter
virus
particularli
adenoviru
hivrel
diarrhoea
signific
patholog
chang
associ
adenoviru
coliti
role
haart
play
control
noncmv
enter
viru
infect
